ECLS trial demonstrates potential of blood test for early lung cancer detection

ECLS trial demonstrates potential of blood test for early lung cancer detection

• Download PDF Copy

Sep 12 2019

Oncimmune Holdings plc (AIM: ONC.L), a leading global immunodiagnostics group, welcomes the presentation of data today by Professor Frank Sullivan (Chief Investigator on the ECLS trial) which has demonstrated the potential of Oncimmune’s EarlyCDT® Lung test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.